Ding et al. (2021) showed serum exosomal levels of DLX6-AS1 can act as a prognostic biomarker in cervical cancer patients. Also, multivariate cox regression has shown that DLX6-AS1 is an independent prognostic factor for survival in a number of cancers such as gastric cancer (Qian et al., 2021), osteosarcoma (Zhang et al., 2018), and ovarian cancer (Zhao and Liu, 2019). Furthermore, a value of 0.795 for area under curve (AUC) in receiver operating characteristic (ROC) curve has shown acceptable efficiency of DLX6-AS1 in diagnosis of glioma (Zhang et al., 2019b). The gene discussed is DLX6; the disease is ovarian cancer.